Tobias Holderried

16PUBLICATIONS
168CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Aug 18, 2026
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

|Jun 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

|Oct 20, 2025
Prospective systematic classification of causes of death in the course of multiple myeloma.

Jia Xiang Jin, Britta Besemer, Büsranur Yilmaz

|Apr 29, 2025
Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.

Martin Wermke, Dejka M Araujo, Manik Chatterjee

|Apr 09, 2025
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.

Martin Wermke, Dejka M Araujo, Manik Chatterjee

Pageof 3

Frequent Collaborators

4 joint publications

Friedrich Stölzel

3 joint publications

Vladan Vucinic

3 joint publications

Hans J Salwender

3 joint publications

Elias K Mai